SIETES :: 93212 citas

Resultados de la búsqueda por DISFUNCIÓN SEXUAL FEMENINA REFINAR BÚSQUEDA

1.

Reisman Y. Post-SSRI sexual dysfunction. BMJ 2020;368:27 de febrero. [Ref.ID 103567]

2.

Anónimo. FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women. U.S. Food and Drug Administration 2019:21 de junio. [Ref.ID 103134]

3.

Thielking M. FDA cracks down on ‘vaginal rejuvenation’ devices, citing potential for serious harm. STAT Daily Recap 2018:30 de julio. [Ref.ID 102728]

4.

Anónimo. With boxed warning, FDA approves estradiol vaginal inserts for dyspareunia. DIA Daily 2018:2. [Ref.ID 102661]

5.

Anónimo. Former investors sue Valeant for failing to successfully market flibanserin. DIA Daily 2016:4. [Ref.ID 101011]

6.

Anónimo. Bremelanotide helps boost libido of women with hypoactive sexual desire disorder in pair of clinical trials. DIA Daily 2016:5. [Ref.ID 100872]

7.

Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ETM. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med 2016;176:453-62. [Ref.ID 100198]

8.

Woloshin S, Schwartz LM. US Food and Drug Administration approval of flibanserin: even the score does not add up. JAMA Intern Med 2016;176:439-42. [Ref.ID 100197]

9.

Joffe HV, Chang C, Sewell C, Easley O, Nguyen C, Dunn S, Lehrfeld K, Lee L, Kim MJ, Slagle AF, Beitz J. FDA approval of flibanserin — Treating hypoactive sexual desire disorder. N Engl J Med 2016;374:101-4. [Ref.ID 100089]

10.

Jaspers L, Feys F, Franco OH, Leusink P, Laan ETM. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women. A systematic review and meta-analysis. JAMA Intern Med 2016;176:453-62. [Ref.ID 100072]

11.

Woloshin S, Schwartz LM. US Food and Drug Administration approval of flibanserin. Even the score does not add up . JAMA Intern Med 2016;176:439-42. [Ref.ID 100071]

12.

Anónimo. Valeant “predatorily priced” female libido drug, investors claim. DIA Daily 2016:1. [Ref.ID 100042]

13.

Anónimo. Flibanserin (Addyi) for hypoactive sexual desire disorder. Med Lett Drugs Ther 2015;57:133-5. [Ref.ID 99654]

14.

Gellad WF, Flynn KE, Alexander C. Evaluation of flibanserin: science and advocacy at the FDA. JAMA 2015;314:869-70. [Ref.ID 99515]

15.

Herman AO. FDA approves drug for hypoactive sexual desire disorder in women. Journal Watch 2015:1. [Ref.ID 99407]

16.

Young K. FDA advisers back approval of first drug for female sexual dysfunction. Journal Watch 2015:1. [Ref.ID 99241]

17.

Roehr B. FDA committee recommends approval for “female Viagra”. BMJ 2015;350:h3097. [Ref.ID 99189]

18.

Moynihan R. Evening the score on sex drugs: feminist movement or marketing masquerade?. BMJ 2014;349:g6246. [Ref.ID 98287]

19.

Lenzer J. Boehringer Ingelheim halts further development of its libido drug for women after negative FDA review. BMJ 2010;341:799. [Ref.ID 89512]

20.

Goldbeck-Wood S. Female sexual dysfunction is a real but complex problem. BMJ 2010;341:701. [Ref.ID 89455]